|
FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
|
US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
CZ121599A3
(cs)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
BR0108545A
(pt)
|
2000-02-24 |
2004-06-29 |
Xcyte Therapies Inc |
Estimulação e concentração simultâneas das células
|
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
BR0307544A
(pt)
|
2002-02-01 |
2004-12-07 |
Ariad Gene Therapeutics Inc |
Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
WO2006127585A2
(en)
|
2005-05-20 |
2006-11-30 |
Virxsys Corporation |
Transduction of primary cells
|
|
US20070036773A1
(en)
|
2005-08-09 |
2007-02-15 |
City Of Hope |
Generation and application of universal T cells for B-ALL
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
AU2007248019B2
(en)
|
2006-05-03 |
2012-10-11 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Chimeric T cell receptors and related materials and methods of use
|
|
WO2008039818A2
(en)
|
2006-09-26 |
2008-04-03 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
|
US20090155275A1
(en)
|
2007-07-31 |
2009-06-18 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
|
US20100260668A1
(en)
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
KR102202460B1
(ko)
|
2011-05-03 |
2021-01-14 |
이뮤노베이티브 테라피스, 엘티디. |
생세포를 포함하는 생물학적 약물을 처리하기 위한 방법
|
|
EP3594245A1
(en)
|
2012-02-13 |
2020-01-15 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
RU2014138474A
(ru)
|
2012-02-24 |
2016-04-10 |
СтемСентРкс, Инк. |
Новые модуляторы и способы применения
|
|
AU2013289971A1
(en)
|
2012-07-13 |
2015-01-22 |
The Trustees Of The University Of Pennsylvania |
Enhancing activity of CAR T cells by co-introducing a bispecific antibody
|
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
US20160017286A1
(en)
|
2013-03-06 |
2016-01-21 |
The Trustees Of The University Of Pennsylvania |
Ikaros inhibition to augment adoptive t cell transfer
|
|
CA2931641C
(en)
|
2013-12-30 |
2022-05-10 |
Epimab Biotherapeutics Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
CN106459915A
(zh)
|
2014-02-04 |
2017-02-22 |
凯德药业公司 |
用于治疗b细胞恶性肿瘤和其它癌症的自体t细胞的生产方法及其组合物
|
|
US20150328292A1
(en)
*
|
2014-03-07 |
2015-11-19 |
Bellicum Pharmaceuticals, Inc. |
Caspase polypeptides having modified activity and uses thereof
|
|
CN106795221B
(zh)
|
2014-04-03 |
2022-06-07 |
塞勒克提斯公司 |
用于癌症免疫治疗的cd33特异性嵌合抗原受体
|
|
AU2015243849B2
(en)
|
2014-04-10 |
2020-12-17 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Transgene genetic tags and methods of use
|
|
CN106536564B
(zh)
|
2014-06-02 |
2021-08-31 |
美国卫生和人力服务部 |
靶向cd-19的嵌合抗原受体
|
|
EP3151854B1
(en)
|
2014-06-06 |
2020-02-26 |
Memorial Sloan Kettering Cancer Center |
Mesothelin-targeted chimeric antigen receptors and uses thereof
|
|
US20170274014A1
(en)
|
2014-07-21 |
2017-09-28 |
Jennifer Brogdon |
Combinations of low, immune enhancing, doses of mtor inhibitors and cars
|
|
CN105367661B
(zh)
|
2014-08-26 |
2019-08-02 |
西比曼生物科技（上海）有限公司 |
嵌合抗原受体及其基因和重组表达载体、工程化her1靶向性的nkt细胞及其应用
|
|
ES3034398T3
(en)
|
2014-08-28 |
2025-08-18 |
Bioatla Inc |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
CN113736828A
(zh)
|
2014-11-05 |
2021-12-03 |
朱诺治疗学股份有限公司 |
用于转导及细胞处理的方法
|
|
WO2016073629A1
(en)
|
2014-11-05 |
2016-05-12 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) to selectively target protein complexes
|
|
KR101744959B1
(ko)
|
2014-12-05 |
2017-06-12 |
(주)케어젠 |
피부상태 개선 활성을 갖는 펩타이드 및 이의 용도
|
|
CA3008162A1
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
|
CN107567461A
(zh)
|
2014-12-29 |
2018-01-09 |
诺华股份有限公司 |
制备嵌合抗原受体表达细胞的方法
|
|
EP3240551A4
(en)
|
2014-12-31 |
2018-08-08 |
Anthrogenesis Corporation |
Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
|
|
US10765699B2
(en)
|
2015-02-06 |
2020-09-08 |
National University Of Singapore |
Methods for enhancing efficacy of therapeutic immune cells
|
|
EP3261651B1
(en)
|
2015-02-27 |
2022-05-04 |
iCell Gene Therapeutics LLC |
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
|
|
GB201503742D0
(en)
|
2015-03-05 |
2015-04-22 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
WO2016142532A1
(en)
*
|
2015-03-11 |
2016-09-15 |
Cellectis |
Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
|
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
HK1247958A1
(zh)
|
2015-05-05 |
2018-10-05 |
菲特治疗公司 |
T淋巴细胞的调节
|
|
EP3307282A4
(en)
|
2015-06-12 |
2019-05-01 |
Immunomedics, Inc. |
DISEASE THERAPY WITH CONSTRUCTS OF CHIMERIC ANTIGEN RECEPTOR (CAR) AND T-CELL (CAR-T) OR NK-CELL (CAR-NK) EXPRESSIVE CAR CONSTRUCTS
|
|
WO2017015427A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
JP7162530B2
(ja)
|
2015-08-07 |
2022-10-28 |
シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） |
固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞
|
|
AU2016337525B2
(en)
|
2015-10-16 |
2022-01-20 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for inhibition of lineage specific antigens
|
|
WO2017070042A1
(en)
|
2015-10-20 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing t cell populations using akt inhibitors
|
|
US11466253B2
(en)
|
2015-10-22 |
2022-10-11 |
Juno Therapeutics Gmbh |
Methods for culturing cells and kits and apparatus for same
|
|
US20180371052A1
(en)
|
2015-12-22 |
2018-12-27 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors and enhancement of anti-tumor activity
|
|
IL311107A
(en)
|
2016-02-17 |
2024-04-01 |
Seagen Inc |
BCMA antibodies and their use for the treatment of cancer and immune disorders
|
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
ES3039670T3
(en)
|
2016-04-15 |
2025-10-23 |
Memorial Sloan Kettering Cancer Center |
Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
|
|
CN109153727A
(zh)
*
|
2016-04-15 |
2019-01-04 |
酵活有限公司 |
靶向免疫治疗剂的多特异性抗原结合构建体
|
|
US11390658B2
(en)
|
2016-06-06 |
2022-07-19 |
St. Jude Children's Research Hospital |
Anti-CD7 chimeric antigen receptor and method of use thereof
|
|
EP3468994A1
(en)
*
|
2016-06-08 |
2019-04-17 |
Intrexon Corporation |
Cd33 specific chimeric antigen receptors
|
|
JP7114490B2
(ja)
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
SG11201900344YA
(en)
|
2016-07-15 |
2019-02-27 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
CN106191062B
(zh)
*
|
2016-07-18 |
2019-06-14 |
广东华南疫苗股份有限公司 |
一种tcr-/pd-1-双阴性t细胞及其构建方法
|
|
CN110214150A
(zh)
|
2016-07-28 |
2019-09-06 |
诺华股份有限公司 |
嵌合抗原受体和pd-1抑制剂的组合疗法
|
|
US10630175B2
(en)
|
2016-08-03 |
2020-04-21 |
Texas Instruments Incorporated |
Pseudo current tracking for power supply regulation
|
|
AU2017306557B2
(en)
|
2016-08-03 |
2023-08-03 |
Washington University |
Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
|
|
SG11201901642XA
(en)
|
2016-08-26 |
2019-03-28 |
Baylor College Medicine |
Constitutively active cytokine receptors for cell therapy
|
|
EP3512950A1
(en)
|
2016-09-14 |
2019-07-24 |
Benitec Biopharma Limited |
REAGENTS FOR PRODUCING T-CELLS WITH NON-FUNCTIONAL T-CELL RECEPTORS (TCRs) COMPOSITIONS COMPRISING SAME AND USE THEREOF
|
|
US20190119636A1
(en)
|
2017-10-23 |
2019-04-25 |
Poseida Therapeutics, Inc. |
Modified stem cell memory t cells, methods of making and methods of using same
|
|
CN106544321B
(zh)
|
2016-10-13 |
2019-01-29 |
北京艺妙神州医疗科技有限公司 |
通用型car-t细胞及其制备方法和用途
|
|
CN106591363A
(zh)
*
|
2016-11-11 |
2017-04-26 |
广东万海细胞生物科技有限公司 |
一种通用型异体car‑t细胞制备方法及应用
|
|
US11440958B2
(en)
|
2016-11-22 |
2022-09-13 |
National University Of Singapore |
Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
|
|
MA46998A
(fr)
|
2016-12-05 |
2019-10-09 |
Juno Therapeutics Inc |
Production de cellules modifiées pour une thérapie cellulaire adoptive
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
GB201622044D0
(en)
|
2016-12-22 |
2017-02-08 |
Ucl Business Plc |
T cell-targeted T cells
|
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
BR112019023608A2
(pt)
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
|
|
SG11201912010XA
(en)
|
2017-06-12 |
2020-01-30 |
Obsidian Therapeutics Inc |
Pde5 compositions and methods for immunotherapy
|
|
CA3070575A1
(en)
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
MA50188A
(fr)
|
2017-09-22 |
2021-06-02 |
Wuxi Biologics Ireland Ltd |
Nouveaux complexes polypeptidiques bispécifiques
|
|
US20200330515A1
(en)
*
|
2017-10-17 |
2020-10-22 |
The General Hospital Corporation |
Methods and compositions relating to engineered regulatory t cells
|
|
MX2020004572A
(es)
|
2017-11-01 |
2020-10-07 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
|
|
GB201719646D0
(en)
|
2017-11-27 |
2018-01-10 |
Bivictrix Therapeutics Ltd |
Therapy
|
|
WO2019108900A1
(en)
|
2017-11-30 |
2019-06-06 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
CN108018312B
(zh)
|
2017-12-20 |
2019-09-10 |
上海优卡迪生物医药科技有限公司 |
一种t淋巴细胞白血病的car-t治疗载体及其构建方法和应用
|
|
SG11202006050XA
(en)
|
2017-12-29 |
2020-07-29 |
Memorial Sloan Kettering Cancer Center |
Enhanced chimeric antigen receptors and uses thereof
|
|
CN108017717B
(zh)
|
2018-01-24 |
2019-08-16 |
首都医科大学宣武医院 |
一种用于体外高效定向扩增的嵌合抗原受体及其应用
|
|
US10869888B2
(en)
*
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
EP3796977A4
(en)
|
2018-05-17 |
2022-03-02 |
The Board of Trustees of the Leland Stanford Junior University |
RECEPTOR INHIBITION BY PHOSPHATASE RECRUITMENT
|
|
CN110526983B
(zh)
|
2018-05-24 |
2022-02-11 |
北京马力喏生物科技有限公司 |
改良型抗cd19 car-t细胞
|
|
IL279063B2
(en)
|
2018-05-31 |
2026-05-01 |
Washington Univ |
Chimeric antigen receptor T cells for cancer treatment
|
|
US20200040056A1
(en)
|
2018-05-31 |
2020-02-06 |
Washington University |
Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies
|
|
CN112533957B
(zh)
*
|
2018-06-04 |
2026-01-16 |
普瑞赛格恩公司 |
Muc16特异性嵌合抗原受体及其用途
|
|
SG11202101204TA
(en)
|
2018-08-09 |
2021-03-30 |
Juno Therapeutics Inc |
Processes for generating engineered cells and compositions thereof
|
|
WO2020037178A1
(en)
*
|
2018-08-16 |
2020-02-20 |
Memorial Sloan-Kettering Cancer Center |
Leucine zipper-based compositions and methods of use
|
|
PT3844267T
(pt)
|
2018-08-31 |
2025-09-30 |
Novartis Ag |
Métodos de preparação de células que expressam recetor de antigénio quimérico
|
|
KR20210061361A
(ko)
|
2018-09-10 |
2021-05-27 |
아타라 바이오테라퓨틱스 인크. |
항원-특이적 car-t 세포를 확장하기 위한 방법, 이와 관련된 조성물 및 용도
|
|
WO2020088631A1
(en)
*
|
2018-11-01 |
2020-05-07 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for t cell engineering
|
|
TW202100747A
(zh)
|
2018-12-07 |
2021-01-01 |
中國大陸商亘喜生物科技（上海）有限公司 |
用於免疫治療之組合物及方法
|
|
WO2020210398A1
(en)
|
2019-04-11 |
2020-10-15 |
Fate Therapeutics, Inc. |
CD3 RECONSTITUTION IN ENGINEERED iPSC AND IMMUNE EFFECTOR CELLS
|
|
CN110358734B
(zh)
|
2019-06-13 |
2020-08-25 |
首都医科大学宣武医院 |
以Tcm为主要效应成分的CAR-T制备方法及其应用
|